Disease · MONDO_0004609

herpes simplex infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. herpes simplex infectious disease. Diseases, record MONDO_0004609. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004609

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: herpes simplex infectious disease; Open Targets
Open Targets ID: MONDO_0004609; Open Targets
Other names: Herpes simplex infection, Simplexvirus caused disease or disorder, Simplexvirus disease or disorder, Simplexvirus infectious disease; Open Targets
Disease Ontology: DOID:8566; Disease Ontology
MeSH: D006561; MeSH
Highest stage of its drugs: Approval, for 5 of its 9 drugs, from DailyMed and FDA; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACYCLOVIR	CHEMBL184	Small molecule	Approval	DailyMed and FDA	13	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TRIFLURIDINE	CHEMBL1129	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
AMENAMEVIR	CHEMBL4297592	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FAMCICLOVIR	CHEMBL880	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PRITELIVIR	CHEMBL4069597	Small molecule	Unknown	USAN	1	0	0	Drugs and targets
PRITELIVIR MESYLATE	CHEMBL4562772	Small molecule	Unknown	USAN	1	0	0	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908

Source Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01959295	Phase III Study of ASP2151 in Herpes Simplex Patients	Phase 3	468	2024-10-09	Herpes Simplex	AMENAMEVIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT02209324	Open-label Study of ASP2151 in Herpes Simplex Patients	Phase 3	275	2024-09-27	Herpes Simplex	AMENAMEVIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT00098059	Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection	Phase 3	74	2009-05-06	Herpes Simplex	FAMCICLOVIR	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ASP2151 vs ASP2151 Placebo: deaths from any cause	128 of 309	59 of 157	466	NCT01959295	Trial comparisons
ASP2151 vs ASP2151 Placebo: serious adverse events	0 of 309	0 of 157	466	NCT01959295	Trial comparisons
Part A (Single-dose of Famciclovir) vs Part B (Multiple-dose of Famciclovir): serious adverse events	0 of 27	0 of 47	74	NCT00098059	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
19273678	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004609

GET https://conductscience.org/api/diseases/v1/MONDO_0004609/drugs

API reference For AI assistants